Shanghai RAAS Blood Products Management
Management criteria checks 1/4
Shanghai RAAS Blood Products' CEO is Jun Xu, appointed in Oct 2022, has a tenure of 3.17 years. directly owns 0.029% of the company’s shares, worth CN¥12.47M. The average tenure of the management team and the board of directors is 5.6 years and 1.4 years respectively.
Key information
Jun Xu
Chief executive officer
CN¥8.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.2yrs |
| CEO ownership | 0.03% |
| Management average tenure | 5.6yrs |
| Board average tenure | 1.4yrs |
Recent management updates
Recent updates
CEO
Jun Xu (61 yo)
Mr. Jun Xu serves as General Manager at Shanghai RAAS Blood Products Co., Ltd. since October 19, 2022 and serves as its Vice Chairman since July 30, 2024 and served as its Deputy General Manager until Octo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Vice Chairman | 3.2yrs | CN¥8.10m | 0.029% CN¥ 12.5m | |
| Financial Manager | 4.2yrs | CN¥2.93m | 0.0015% CN¥ 655.0k | |
| Deputy GM & Secretary of Board of Directors | 18.7yrs | CN¥3.26m | 0.012% CN¥ 5.1m | |
| Deputy General Manager | 21.6yrs | CN¥3.56m | 0.011% CN¥ 4.6m | |
| Deputy General Manager | 12.8yrs | CN¥3.36m | 0.0085% CN¥ 3.6m | |
| Deputy General Manager | 5.6yrs | CN¥3.34m | 0.0044% CN¥ 1.9m | |
| Head of Accounting | no data | no data | no data | |
| Director of Sales & Marketing | no data | no data | no data | |
| Deputy General Manager | 1.4yrs | no data | no data |
Experienced Management: 002252's management team is seasoned and experienced (5.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Vice Chairman | 9.7yrs | CN¥8.10m | 0.029% CN¥ 12.5m | |
| Employee Representative Supervisor | 5.6yrs | CN¥2.15m | 0.012% CN¥ 5.0m | |
| Independent Director | 1.4yrs | CN¥99.20k | no data | |
| Non-Independent Director | 1.4yrs | CN¥90.80k | no data | |
| Independent Director | 1.4yrs | CN¥99.20k | no data | |
| Non-employee Supervisor | 1.4yrs | no data | no data | |
| Independent Director | 1.4yrs | CN¥99.20k | no data | |
| Chairman of the Supervisory Board | 1.4yrs | no data | no data | |
| Non- Independent Director | 1.4yrs | no data | no data | |
| Non- Independent Director | 1.4yrs | no data | no data | |
| Non-Independent Director | 1.4yrs | CN¥99.20k | no data | |
| Chairman | 1.4yrs | no data | no data |
Experienced Board: 002252's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/13 06:54 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai RAAS Blood Products Co., Ltd. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Sophia Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Jie Yao | Citic Securities Co., Ltd. |